SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Provided By GlobeNewswire
Last update: Feb 20, 2025
- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients -
Read more at globenewswire.comNASDAQ:SLS (8/15/2025, 11:05:09 AM)
1.5801
+0.03 (+1.94%)
Find more stocks in the Stock Screener
SLS Latest News and Analysis
